XML 124 R15.htm IDEA: XBRL DOCUMENT
v3.20.2

Inventory | 12 Months Ended
--- | ---
Jun. 30, 2020
Inventories [Abstract] |
Inventory | Inventory
Accounting Policy The Company defines inventory as all cannabis products after the point of harvest (“Cannabis Inventory”), hemp products, purchased finished goods for resale, consumable supplies and accessories. Cannabis Inventory includes harvested cannabis, trim, cannabis oils, capsules, edibles and vaporizers. Inventories of harvested cannabis are transferred from biological assets at fair value less costs to sell at the point of harvest, which becomes the deemed cost. By-products, such as trim, are measured at their net-realizable-value (“NRV”) at point of harvest which is deducted from the total deemed cost to give a net cost for the primary product. Any subsequent post-harvest costs are capitalized to Cannabis Inventory to the extent that the cost is less than NRV. NRV for work-in-process (“WIP”) and finished Cannabis Inventory is determined by deducting estimated remaining conversion/completion costs and selling costs from the estimated sale price achievable in the ordinary course of business. Conversion and selling costs are determined using average cost. In the period that Cannabis Inventory is sold, the fair value portion of the deemed cost is recorded within changes in fair value of inventory sold line, and the cost of such Cannabis Inventory, including direct and indirect costs, are recorded within the cost of sales line on the statement of comprehensive loss. Products for resale, consumable supplies and accessories are initially recognized at cost and subsequently valued at the lower of cost and NRV. The Company reviews these types of inventory for obsolescence, redundancy and slow turnover to ensure that they are written-down and reflected at NRV. The Company uses judgment in determining the NRV of inventory. When assessing NRV, the Company considers the impact of price fluctuation, inventory spoilage, inventory excess, age and damage.
The following is a breakdown of inventory:
| June 30, 2020 |  | June 30, 2019 (1)
| Capitalized cost |  | Fair value adjustment |  | Carrying value |  |  | Capitalized cost |  | Fair value adjustment |  | Carrying value |
| $ |  | $ |  | $ |  |  | $ |  | $ |  | $ |
Harvested cannabis |  |  |  |  |  |  |
Work-in-process | 29,737 |  | 16,708 |  | 46,445 |  |  | 30,518 |  | 31,386 |  | 61,904 |
Finished goods | 11,826 |  | 1,735 |  | 13,561 |  |  | 8,529 |  | 5,007 |  | 13,536 |
| 41,563 |  | 18,443 |  | 60,006 |  |  | 39,047 |  | 36,393 |  | 75,440 |
Extracted cannabis |  |  |  |  |  |  |
Work-in-process | 21,608 |  | 4,995 |  | 26,603 |  |  | 4,536 |  | 1,356 |  | 5,892 |
Finished goods | 15,758 |  | 1,396 |  | 17,154 |  |  | 7,563 |  | 1,224 |  | 8,787 |
| 37,366 |  | 6,391 |  | 43,757 |  |  | 12,099 |  | 2,580 |  | 14,679 |
Hemp products |  |  |  |  |  |  |
Raw materials | 929 |  | — |  | 929 |  |  | 4,508 |  | — |  | 4,508 |
Work-in-process | 235 |  | — |  | 235 |  |  | 1,000 |  | — |  | 1,000 |
Finished goods | 107 |  | — |  | 107 |  |  | 3,183 |  | — |  | 3,183 |
| 1,271 |  | — |  | 1,271 |  |  | 8,691 |  | — |  | 8,691 |
Supplies and consumables | 16,125 |  | — |  | 16,125 |  |  | 9,673 |  | — |  | 9,673 |
Merchandise and accessories | 668 |  | — |  | 668 |  |  | 2,838 |  | — |  | 2,838 |
Ending Balance | 96,993 |  | 24,834 |  | 121,827 |  |  | 72,348 |  | 38,973 |  | 111,321 |
(1) | Amounts have been retroactively restated for the change in accounting policy relating to the valuation of Cannabis Inventory (Note 2(h).
During the year ended June 30, 2020, inventory expensed to cost of goods sold was $369.1 million (year ended June 30, 2019 – $195.6 million), which included $91.8 million (year ended June 30, 2019 – $71.8 million) of non-cash expense related to the changes in fair value of inventory sold. During the year ended June 30, 2020, management recognized a $135.1 million (year ended June 30, 2019 – nil) charge to the net realizable value of our inventory due to a decrease in selling price and inventory deemed as excess based on current and projected market demands. O f the $135.1 million (year ended June 30, 2019 – nil) inventory impairment, $105.5 million is recognized through cost of sales and $29.6 million is recognized through changes in fair value of inventory sold on the statements of comprehensive loss.

X
- Definition Inventories [Abstract] + References No definition available. + Details
Name: | acb_InventoriesAbstract
Namespace Prefix: | acb_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for inventories. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 2 -IssueDate 2019-01-01 -Section Disclosure -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=2&code=ifrs-tx-2019-en-r&doctype=Standard&dita_xref=IAS02_g36-39_TI -URIDate 2019-03-27 + Details
Name: | ifrs-full_DisclosureOfInventoriesExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration